CXCL12 and prostate carcinoma: Wang and collaborators showed that by disrupting cellular interactions mediated by the CXCR4/CXCL12 axis with the CXCR4 inhibitor AMD3100, the preferential homing pattern of prostate cancer cells to osteoblast-rich bone surfaces was disrupted [13].